The 5 most entry-ready markets for medical devices right now

Not all markets are equally hard to enter. For medical devices, the fastest routes right now belong to the markets that let you build on an approval you already hold somewhere else. That single feature, regulatory reliance, is quietly reshaping where and in what order companies choose to launch.

Drawing on Vantro coverage of 90 markets, here are the five most entry-ready for a Class II device, ranked on regulatory reliance and route speed, reimbursement clarity, and market scale. Reliance weighs most, because it is the difference between months of duplicated review and a pathway that recognises work already done.

1. Singapore

Singapore is the clearest case of reliance done well. It accepts prior approval from five reference agencies, including the US FDA, EU notified bodies, Health Canada, Australia's TGA, and Japan's PMDA. For a manufacturer that already holds one of those approvals, the abridged route removes a large share of the duplicated assessment. Singapore also functions as the gateway to ASEAN, and its reliance programme with Malaysia is now permanent.

2. Australia

The TGA accepts MDSAP audit reports alongside CE and FDA approvals, allowing eligible devices to move through an abridged conformity assessment rather than starting from scratch. For lower-risk classes, timelines run in weeks rather than months. The system is mature and closely aligned with the EU framework, and a competent local sponsor is the main operational prerequisite.

3. India

India combines a workable timeline with scale that few markets can match. A Class B device is licensed through the digitised SUGAM portal on a statutory timeline of 60 to 120 days. Real-world timelines, including any inspection, can run longer, but the pathway is clear and increasingly digital. Behind it sits one of the fastest-growing device markets in the world.

4. Malaysia

Malaysia's value is its reliance relationship with Singapore, now a permanent programme rather than a pilot. A device approved by one regulator moves faster through the other, which lets a company sequence the two together and enter a second ASEAN market with far less duplicated effort.

5. UAE

The UAE is the gateway to the wider MENA region. Device registration moved to the Emirates Drug Establishment, which offers a verification pathway for devices already approved by reference authorities such as the EMA, FDA, and PMDA. Combined with full foreign ownership in free zones, it is a credible launchpad into a region that is otherwise fragmented and hard to read.

The pattern worth noticing

Every market on this list rewards the same thing: an approval you already hold somewhere else. The question is no longer only whether you can get approved here. It is which approval unlocks the most markets next. Sequencing has become a strategic decision, not an administrative one.

This is the general picture. Your device, your class, and your target markets change the ranking. A Class III implantable faces a different landscape than the Class II devices ranked here, and reimbursement and procurement realities can move a market up or down regardless of regulatory speed. That is what a sourced Market Brief is for.

First edition of the Vantro Market Readiness Index, a quarterly series. Pharmaceuticals next.